The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
The initiative pairs consumer engagement with a public health message about prevention and early detection
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Health innovations are viewed more positively than food and agricultural technologies
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Subscribe To Our Newsletter & Stay Updated
